موكسيپن فورتة ٥٠٠ ملغ إسرائيل - العربية - Ministry of Health

موكسيپن فورتة ٥٠٠ ملغ

salomon,levin & elstein ltd - amoxicillin trihydrate 500 mg - capsules - amoxicillin - infections caused by amoxycillin - susceptible organisms. prevention of bacteremia in patients at risk of developing bacterial endocarditis.

أكتونيل مرة في الشهر ١٥٠ ملغ إسرائيل - العربية - Ministry of Health

أكتونيل مرة في الشهر ١٥٠ ملغ

sanofi - aventis israel ltd - risedronic acid as sodium 150 mg - film coated tablets - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

پريمولوت-نور إسرائيل - العربية - Ministry of Health

پريمولوت-نور

bayer israel ltd - norethisterone acetate 5 mg - tablets - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

تريتايس كومب ٢٫٥ ملغم/١٢٫٥ ملغ إسرائيل - العربية - Ministry of Health

تريتايس كومب ٢٫٥ ملغم/١٢٫٥ ملغ

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

لوثيماكس إسرائيل - العربية - Ministry of Health

لوثيماكس

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po